COMMUNIQUÉS West-GlobeNewswire

Congrès ESC 2024 : L’essai INFINITY-SWEDEHEART portant sur le DynamX Bioadaptor d’Elixir Medical satisfait au critère d’évaluation principal et les résultats cliniques confirment un mécanisme d'action unique

02/09/2024 - 13:45

Congrès ESC 2024 : L’essai INFINITY-SWEDEHEART portant sur le DynamX Bioadaptor d’Elixir Medical satisfait au critère d’évaluation principal et les résultats cliniques confirment un mécanisme d'action unique — Le pool [...]

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/09/2024 - 13:30

CLEVELAND, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved [...]

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today

02/09/2024 - 13:00

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innovation-led cell and [...]

GUERBET : Bilan semestriel du contrat de liquidité

02/09/2024 - 12:59

Bilan semestriel du contrat de liquidité Villepinte, le 2 septembre 2024 Au titre du contrat de liquidité confié par la société GUERBET à Exane BNP Paribas, en date de dénouement du 30 juin 2024, les moyens suivants [...]

Trading in GN Store Nord shares by board members, executives and associated persons

02/09/2024 - 12:39

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]

Myocene Helps the French Handball Team

02/09/2024 - 09:00

LIÈGE, Belgium, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Myocene, the Belgian sportstech company which is developing a device for the objective measurement of muscular fatigue for top-level sportsmen and women, today [...]

Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

02/09/2024 - 09:00

The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker studies to showcase the candidate's differentiated dual tumour-lytic and [...]

Myocene Helps the French Handball Team

02/09/2024 - 09:00

LIÈGE, Belgium, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Myocene, the Belgian sportstech company which is developing a device for the objective measurement of muscular fatigue for top-level sportsmen and women, today [...]

MYOCENE AU SERVICE DE L'ÉQUIPE DE FRANCE DE HANDBALL

02/09/2024 - 09:00

LIÈGE, Belgique, 02 sept. 2024 (GLOBE NEWSWIRE) -- Myocene, la sportstech liégeoise qui développe un dispositif de mesure objective de la fatigue musculaire à destination des sportifs de haut niveau, annonce aujourd’hui [...]

PCI Biotech: Employee share option scheme

02/09/2024 - 07:53

Oslo, 2 September 2024 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees. In accordance with the authorisation granted by the Annual General Meeting 24 May [...]

Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis

02/09/2024 - 07:00

Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES study, [...]

CP- Tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament qui a permis d’observer une réduction de l’accumulation du handicap chez des personnes avec une sclérose en plaques...

02/09/2024 - 07:00

Le tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament ayant permis d’observer une réduction de l’accumulation du handicap chez des personnes présentant [...]

Claritas HealthTech Furthers its Capabilities in Urology with ReDisys™, a Computer Aided Detection Software for Kidney Cancer in CT Scans

02/09/2024 - 05:00

HONG KONG and LONDON, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Claritas HealthTech (“Claritas”) , a healthcare technology company specializing in medical image enhancement and Artificial Intelligence (AI) assisted diagnostic [...]

Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

02/09/2024 - 01:30

Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment [...]

Avance Clinical GlobalReady Site Partnership Network Expands Rapidly to 2,000 Site Members

01/09/2024 - 23:57

WAKE FOREST, N.C. and ADELAIDE, Australia , Sept. 01, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning market-leading CRO for biotechs, announced today that 2,000 clinical sites across North America had [...]

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

01/09/2024 - 14:00

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE [...]

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024

01/09/2024 - 10:27

Data from Integrated Safety Analysis Across Three Clinical Trials Reinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM Demonstrates Successful Withdrawal of Standard of Care Medications in Patients [...]

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024

01/09/2024 - 09:51

Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodeling by Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography, Symptom Relief and Improvement in Biomarkers with Aficamten [...]

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024

31/08/2024 - 09:54

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials testing multi- [...]